Sagimet Biosciences Inc. Series A Common Stock (SGMT) is a publicly traded Healthcare sector company. As of May 21, 2026, SGMT trades at $6.61 with a market cap of $411.27M and a P/E ratio of -4.19. SGMT moved +1.83% today. Year to date, SGMT is +20.04%; over the trailing twelve months it is +93.88%. Its 52-week range spans $1.73 to $11.41. Analyst consensus is strong buy with an average price target of $27.50. Rallies surfaces SGMT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes SGMT SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $6.61 |
| Market Cap | $411.27M |
| P/E Ratio | -4.19 |
| EPS | $-1.58 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.41 |
| 52-Week Low | $1.73 |
| Volume | 2.67K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-51.04M |
| Gross Margin | 0.00% |
10 analysts cover SGMT: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $27.50.